INTRODUCTION {#s1}
============

Breast cancer is the most common invasive cancer and the leading cause of death from cancer among women worldwide. Patients younger than 35 years of age are relatively rare, accounting for 2% - 4% of all cases diagnosed annually in the west \[[@R1]--[@R3]\] but much more popular in Asia \[[@R3]--[@R6]\]. According to the Annual Report of Cancer Statistics in Korean in 2011, 13.2% of breast cancer was \< 40 years of age, and 4.7% was \< 35 years of age \[[@R6]\].

It is believed breast cancer at a young age is associated with more aggressive biological behavior and worse prognosis than in elderly \[[@R5], [@R7]--[@R17]\], characterized by higher incidence of recurrence and higher risk of death, even when treated with more aggressive therapies \[[@R10]--[@R14]\]. However, instead of reporting the overall prognosis from early stage to recurrence, few studies have investigated on survival outcomes after patients develop locoregional relapse (LRR) or distant metastasis (DM). It is speculated that young patients is much more tolerable to intensive treatment therefore might have better survival after LRR or DM, despite a shorter disease-free survival (DFS) following the surgery.

In this study, we aimed to evaluate the recurrence pattern and survival outcomes following recurrence in young breast cancer patients when compared with elderly patients.

RESULTS {#s2}
=======

Patient characteristics {#s2_1}
-----------------------

From January 2008 to December 2012, 1222 breast cancer patients were included in the study. 483 (39.5%) of total population were younger than 35 years old. As shown in Table [1](#T1){ref-type="table"}, more patients had a family history of breast cancer or ovarian cancer in the young population compared with elderly (8.7% *vs* 4.1%, *P* = 0.001). The young patients presented with a higher rate of pathologic tumor stage (*P* \< 0.001), positive pathologic lymph node (*P* \< 0.001), grade III tumors (*P* \< 0.001), and lymphovascular invasion (*P* \< 0.001). The incidence of triple negative breast cancer was also higher in young patients (15.1% *vs* 12.3%, *P* \< 0.001). Furthermore, young patients were more likely to receive breast-conserving surgeries (*P* \< 0.001), adjuvant chemotherapy (*P* \< 0.001) and radiotherapy (*P* \< 0.001).

###### Patients' baseline characteristics

                                          All    Age≤35       Age≥65       χ^2^      *P*
  --------------------------------------- ------ ------------ ------------ --------- ---------
  Family history                                                           11.322    0.001
   Breast cancer or ovarian cancer        72     42 (8.7)     30 (4.1)               
   No                                     1150   441 (91.3)   709 (95.9)             
  Type of surgery                                                          17.776    \<0.001
   Mastectomy                             893    321 (66.5)   572 (77.4)             
   Breast-conserving surgery              329    162 (33.5)   167 (22.6)             
  Histology                                                                4.266     0.118
   In situ                                76     23 (4.8)     53 (7.2)               
   Invasive                               1080   438 (90.7)   642 (86.9)             
   Others                                 66     22 (4.6)     44 (6.0)               
  Tumor grade                                                              15.512    \<0.001
   Grade I                                76     20 (5.3)     56 (7.9)               
   Grade II                               599    221 (58.8)   378 (65.1)             
   Grade III                              282    135 (35.9)   147 (25.3)             
  Pathologic tumor stage                                                   34.599    \<0.001
   T0                                     73     22 (4.6)     51 (6.9)               
   T1                                     626    225 (46.6)   401 (54.3)             
   T2                                     460    199 (41.2)   261 (35.3)             
   T3                                     31     26 (5.4)     5 (0.7)                
   T4                                     32     11 (2.3)     21 (2.8)               
  Pathologic tumor stage                                                   11.991    0.001
   T0-1                                   699    247 (51.1)   452 (61.2)             
   T2-4                                   523    236 (48.9)   287 (38.8)             
  Pathologic node status                                                   19.717    \<0.001
   N0                                     630    233 (48.7)   397 (61.1)             
   N1                                     280    129 (27.0)   151 (23.2)             
   N2                                     125    68 (14.2)    57 (8.8)               
   N3                                     93     48 (10.0)    45 (6.9)               
  Pathologic node status                                                   16.989    \<0.001
   N0                                     630    233 (48.7)   397 (61.1)             
   N1-3                                   498    245 (51.3)   253 (38.9)             
  Primary tumor size                                                       24.969    \<0.001
   ≤5cm                                   1175   448 (92.8)   727 (98.4)             
   \>5cm                                  47     35 (7.2)     12 (1.6)               
  ER                                                                       5.564     0.018
   Positive                               917    345 (71.4)   572 (77.4)             
   Negative                               305    138 (28.6)   167 (22.6)             
  PgR                                                                      0.862     0.353
   Positive                               875    353 (73.1)   522 (70.6)             
   Negative                               347    130 (26.9)   217 (29.4)             
  HER2 overexpression                                                      20.770    \<0.001
   Yes                                    254    132 (27.3)   122 (16.5)             
   No                                     968    351 (72.7)   617 (83.5)             
  Molecular subtype                                                        32.774    \<0.001
   ER/PgR+ and HER2-                      802    277 (57.3)   525 (71.0)             
   ER/PgR+ and HER2+                      171    98 (20.3)    73 (9.9)               
   ER/PgR- and HER2+                      85     35 (7.2)     50 (6.8)               
   ER/PgR- and HER2-                      164    73 (15.1)    91 (12.3)              
  Inflammatory breast cancer                                               0.133     0.715
   No                                     1194   471 (97.5)   723 (97.8)             
   Yes                                    28     12 (2.5)     16 (2.2)               
  Lymphovascular invasion                                                  23.199    \<0.001
   No                                     1108   414 (85.7)   694 (93.9)             
   Yes                                    114    69 (14.3)    45 (6.1)               
   Adjuvant chemotherapy                                                   447.438   \<0.001
   No                                     541    47 (9.7)     494 (66.8)             
  Anthracycline-containing chemotherapy   446    333 (68.9)   113 (15.3)             
   Chemotherapy without anthracycline     235    103 (21.3)   132 (17.9)             
  Adjuvant radiotherapy                                                    238.343   \<0.001
   No                                     759    172 (35.6)   587 (79.4)             
   Yes                                    463    311 (64.4)   152 (20.6)             
  Endocrine therapy                                                        0.062     0.803
   No                                     321    125 (25.9)   196 (26.5)             
   Yes                                    901    358 (74.1)   543 (73.5)             
  Trautuzumab                                                              45.465    \<0.001
   No                                     1144   424 (87.8)   720 (97.4)             
   Yes                                    78     59 (12.2)    19 (2.6)               

Abbreviations: ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor receptor 2.

Survival analysis and prognostic factors {#s2_2}
----------------------------------------

After a median follow-up of 56.5 months, patients in the young population had a significantly lower 5-year DFS (Figure [1A](#F1){ref-type="fig"}, 73.7% *vs* 83.4%, *P* = 0.001). Nonetheless, no significant difference in 5-year OS1 was observed (Figure [1B](#F1){ref-type="fig"}, 91.7% *vs* 91.7%, *P* = 0.721).

![Kaplan-Meier curves of disease-free survival (DFS) (A) and overall survival (OS) (B) in the young population (N = 483) and the elderly population (N = 739)\
**A**. Patients in the young population had a significantly lower 5-year DFS (73.7% *vs* 83.4%, *P* = 0.001) (73.7% *vs* 83.4%, *P* = 0.001). **B**. No significant difference in 5-year OS1 was observed (91.7% *vs* 91.7%, *P* = 0.721).](oncotarget-08-44851-g001){#F1}

In ER/PgR+ and HER2- disease, young patients were at increased risk of recurrence (5-year DFS rate: 75.2% *vs* 87.6%, *P* = 0.001) compared with elderly; whereas no difference was observed in OS1 (5-year OS1 rate: 92.5% *vs* 92.9%, *P* = 0.453). On the other hand, there was no significant difference in DFS or OS1 between two populations in ER/PgR+ and HER2+, ER/PgR- and HER2+, or ER/PgR- and HER2- disease (data not shown).

Based on multivariate survival analysis, positive axillary lymph node and large primary tumor were negatively related to DFS (*P* = 0.032, HR = 0.578, 95% CI = 0.350-0.953) (Table [2](#T2){ref-type="table"}) and OS1 (*P* = 0.031, HR = 0.383, 95% CI = 0.160-0.981) (Table [3](#T3){ref-type="table"}) in young patients. Similar results were observed in elderly patients (DFS: *P* \< 0.001, HR = 271, 95% CI = 0.167-0.440, OS1: *P* \< 0.001, HR = 0.241, 95% CI = 0.133-0.437) (Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}). For young population, ER or PgR positive patients presented with longer OS1 (*P* = 0.010, HR = 2.586, 95% CI = 1.254-5.331), but have a tendency to be with shorter DFS (*P* = 0.070, HR = 0.400, 95% CI = 0.149-1.078). In the elder patients, longer OS1 was observed in patients who received adjuvant chemotherapy after surgery (*P* = 0.047, HR = 1.790, 95% CI = 1.009-3.179).

###### Cox proportional hazards model for disease-free survival

  Variables                  Young group                     Old group             
  -------------------------- --------------------- --------- --------------------- ---------
  N1-3                       0.578 (0.350-0.953)   0.032     0.271 (0.167-0.440)   \<0.001
  Primary tumor size \>5cm   0.272 (0.136-0.545)   \<0.001   0.359 (0.157-0.822)   0.015
  Lymphovascular invasion    0.502 (0.299-0.842)   0.009     0.788 (0.433-1.434)   0.436
  ER/PgR positive            0.400 (0.149-1.078)   0.070     0.720 (0.270-1.923)   0.512
  HER2 positive              0.637 (0.253-1.602)   0.338     1.299 (0.628-2.683)   0.480
  Adjuvant chemotherapy      1.085 (0.374-3.144)   0.881     0.939 (0.587-1.504)   0.795
  Adjuvant radiotherapy      1.621(0.986-2.666)    0.057     0.985 (0.608-1.594)   0.950
  Endocrine therapy          4.021(1.378-11.729)   0.011     2.530 (1.337-4.786)   0.004
  ER/PgR+ and HER2-          1.731(0.578-5.182)    0.326     0.634 (0.239-1.681)   0.360

Abbreviations: HR: hazard ratio; CI: confidential interval; ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor receptor 2.

###### Cox proportional hazards model for overall survival

  Variables                  Young group                    Old group             
  -------------------------- ---------------------- ------- --------------------- ---------
  N1-3                       0.383 (0.160-0.981)    0.031   0.241 (0.133-0.437)   \<0.001
  Primary tumor size \>5cm   0.242 (0.101-0.581)    0.001   0.241 (0.097-0.579)   0.002
  Lymphovascular invasion    0.405 (0.183-0.897)    0.026   0.678 (0.327-1.405)   0.295
  ER/PgR positive            2.586 (1.254-5.331)    0.010   0.931 (0.270-3.216)   0.910
  HER2 positive              0.668 (0.192-2.326)    0.527   1.183 (0.490-2.856)   0.709
  Adjuvant chemotherapy      2.571 (0.473-13.974)   0.274   1.790 (1.009-3.179)   0.047
  Adjuvant radiotherapy      1.336 (0.576-3.098)    0.500   0.926 (0.495-1.731)   0.809
  Endocrine therapy          1.819 (0.243-13.591)   0.560   1.530 (0.640-3.657)   0.339
  ER/PgR+ and HER2-          2.019 (0.376-10.840)   0.412   0.493(0.153-1.585)    0.235

Abbreviations: HR: hazard ratio; CI: confidential interval; ER: estrogen receptor; PgR: progesterone receptor; HER2: human epidermal growth factor receptor 2.

Recurrence patterns {#s2_3}
-------------------

At the last follow-up in young patients, we observed LRR in 28 (5.8%) patients, DM in 72 (14.9%), both LRR and DM in 8 (1.7%), contralateral breast cancer in 6 (1.2%), and other cancers in 1 (0.2%) patients. In the elderly, the respective recurrence rates were 2.8% (28/739), 8.1% (60/739), 0.1% (1/739), 1.5% (11/739), and 2.2% (16/739).

As shown in Figure [2](#F2){ref-type="fig"}, the 5-year cumulative incidences of LRR (8.9% *vs* 4.3%, *P* = 0.009) and DM (18.8% *vs* 9.5%, *P* \< 0.001) were significantly higher in the young patients compared with elderly. In contrast, more elderly were diagnosed with other cancers in the follow-up period (2.5% *vs* 0.2%, *P* = 0.004). The 5-year cumulative incidences of contralateral breast cancer were similar between two populations (1.8% *vs* 1.5%, *P* = 0.717).

![Cumulative incidence of locoregional relapse (LRR) (A), distant metastasis (DM) (B), contralateral breast cancer (C), and other cancers (D) according to age at diagnosis\
**A**., **B**. The 5-year cumulative incidences of LRR (Figure [2A](#F2){ref-type="fig"}, 8.9% *vs* 4.3%, *P* = 0.009) and DM (Figure [2B](#F2){ref-type="fig"}, 18.8% *vs* 9.5%, *P* \< 0.001) were significantly higher in the young patients compared with elderly. **C**. The 5-year cumulative incidences of contralateral breast cancer were similar between two populations (1.8% *vs* 1.5%, *P* = 0.717). **D**. More elderly were diagnosed with other cancers in the follow-up period (2.5% *vs* 0.2%, *P* = 0.004).](oncotarget-08-44851-g002){#F2}

Prognosis after recurrence {#s2_4}
--------------------------

In order to further explore the survival difference between young and elderly populations, we carried out stratified analysis. As shown in Figure [3](#F3){ref-type="fig"}, in patients with DM, 5-year OS1 (5-year: 60.0% *vs* 47.3%, median: 70.9 *vs* 49.4 months, *P* = 0.025) and 5-year OS2 (31.0% *vs* 24.3%, 38.8 *vs* 12.1 months, *P* = 0.001) were significantly longer in the young patients compared with elderly; while no difference was observed in 5-year DFS between young cohort with DM and elderly group. In addition, in patients with LRR, contralateral breast cancer, or other cancers, no difference was observed in 5-year DFS, 5-year OS2 and 5-year OS1 between age groups (data not shown).

![In the patients who developed distant metastasis after surgery, disease-free survival (DFS) (A), overall survival after recurrence (OS2) (B), overall survival since diagnosis (OS1) (C) according to age\
No difference was observed in 5-year DFS between young cohort with and elderly group. **B**., **C**. 5-year OS2 (Figure [3B](#F3){ref-type="fig"}, 31.0% *vs* 24.3%, 38.8 *vs* 12.1 months, *P* = 0.001) and 5-year OS1 (Figure [3C](#F3){ref-type="fig"}, 5-year: 60.0% *vs* 47.3%, median: 70.9 *vs* 49.4 months, *P* = 0.025) were significantly longer in the young patients compared with elderly.](oncotarget-08-44851-g003){#F3}

DISCUSSION {#s3}
==========

It has been widely believed that breast cancer at a young age is associated with a more aggressive biological behavior although there was no consensus definition for young breast cancer. Tumors in young women present with higher grade, higher T or N stage, lower differentiation, higher proliferating fraction and more vascular invasion \[[@R5], [@R7]--[@R17]\]. Azim and colleagues \[[@R18]\] reported that young patients had a significantly higher portion of basal-like tumors and HER2-enriched tumors. In our study, the clinicopathological characteristics of young patients were consistent with previous findings.

Following these facts, it is self-explanatory to associate young age with less favorable prognosis \[[@R5], [@R7]--[@R17]\]. Tang et al \[[@R15]\] demonstrated that after a follow-up of 54 months, patients \< 40 years of age had inferior 5-year DFS (72% *vs* 83%, *P* \< 0.01) and 5-year OS (87% *vs* 93%, *P* \< 0.01) compared with those in 40-50. Consistently, lower 5-year DFS in young patients was also observed in our study (62.2% *vs* 77.8%, *P* = 0.037). In addition, a few recent studies suggested that the prognostic value of age differs by biologic subtypes. Sheridan et al \[[@R19]\] reported that age \< 40 was associated with inferior survival within the luminal subtypes. Tang et al \[[@R15]\] indicated that young patients with tumors classified as luminal B type were at increased risk of poor DFS and OS; in contrast, no significant DFS or OS difference between young and elderly was observed in HER2-positive or triple negative breast cancer. Our study, on the other hand, suggested young patients with luminal A subtype had worse survival outcomes. This slight inconsistency could be attributed to the variable definitions of molecular subtypes among different studies.

Importantly, few studies have evaluated the recurrence patterns after surgery and relevant clinical implications in young breast cancer patients. Cancello et al \[[@R12]\] reported that patients \< 35 years of age were at a higher risk to develop LRR (*P* = 0.0001) and DM (*P* = 0.0001) when compared with elderly (aged 35-50). Similar results were reported by De la Rochefordiere \[[@R20]\] and our group. A few studies have demonstrated that young age was an independent risk factor for increased LRR after breast-conserving surgeries in both intraductal and invasive diseases, despite given more aggressive adjuvant therapies \[[@R21]--[@R23]\]. Considering that higher portion of patients received breast-conserving surgery in young population in our study, the high risk of LRR in young patients could be partly attributed to the high rate of breast-conserving surgeries in our study. In addition, DM is the main recurrence pattern in young patients, much higher than LRR, justifying more intensive chemotherapy following surgery.

Despite the progress in recent years, more than 30% of patients diagnosed with early stage breast cancer will eventually progress to or relapse with advanced breast cancer \[[@R24]--[@R25]\]. And the overall survival for advanced breast cancer patients remains poor with a median survival ranging from 2 to 3 years \[[@R26]--[@R28]\]. In our study, we also compared the survival outcomes after recurrence in two populations. Better survival outcomes were observed in young patients with post-surgical DM but not with LRR. It is reasonable to speculate that young patients were able to receive more intensive treatments for better performance status and tolerability. Secondly, many patients in the elderly population died of causes other than breast cancer. Bastiaannet et al \[[@R29]\] investigated the relative survival (calculated as the ratio of the survival observed and the survival expected based on the corresponding general population) of elderly patients over young patients in 127,805 unselected population in Netherlands. It was reported that OS and relative survival decreased with age indicating the excess mortality in the elderly due to causes other than breast cancer. These data all suggested that in order to prolong survival, young breast cancer patients with DM should be given with more intensive treatments even the disease was incurable.

Admittedly, there were several limitations. Owing to the retrospective nature and nonrandomized design of the study, selection bias was inevitable. And the treatments were imbalanced between two populations. In HER2-positive disease, more received trastuzumab in young patients (59/132 *vs* 19/122, 44.7% *vs* 15.6%).

In conclusion, young breast cancer patients present with more aggressive clinicopathological features and have poor prognosis compared with elderly. Although they were at a higher risk to develop LRR and DM after surgery, patients with DM might have better survival outcomes.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

From January 2008 to December 2012, patients with operable breast cancer who received surgery at the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College were systemically reviewed. The inclusion criteria for the study were: (1) ≤ 35 years old or ≥ 65 years old; (2) newly diagnosed breast cancer; (3) available pathology report of immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) status using tumor samples from core needle biopsy or surgery. The exclusion criteria were: (1) stage IV disease, bilateral breast cancer, male breast cancer, or patients complicated with other malignancies; (2) patients with incomplete medical record; (3) patients lost to follow-up immediately after treatment.

This was a retrospective observational study with information collected from hospital database. Patients' treatments or care was not interfered throughout the course. Therefore, ethical approval and patient consents were not required.

Treatment {#s4_2}
---------

Clinical evaluations at the time of this study entry included medical history and physical examination, complete blood cell count, serum biochemistry (including hepatic function, renal function, and electrolytes), electrocardiogram, bilateral breast magnetic resonance imaging or ultrasound, chest X-ray, abdominal ultrasound or computed tomography scans.

All of the mastectomies and breast-conserving surgeries were R0 resection (margin-clear resection). Adjuvant chemotherapy and radiotherapy were used at the discretion of physicians in adherence to the treatment guidelines back then, followed by endocrine therapy in cases of ER or PgR positive. Trastuzumab was recommended to HER2-positive patients but not compulsory. The status of ER, PgR and HER2 were determined by IHC. ER or PgR positive was defined as at least 1% of tumor cells with positive nuclear staining. HER2 positive was defined as 3+ by IHC or positive by fluorescent *in situ* hybridization. The study population was divided as: (1) ER/PgR+ and HER2-; (2) ER/PgR+ and HER2+; (3) ER/PgR- and HER2+; (4) ER/PgR- and HER2-.

Statistical analysis {#s4_3}
--------------------

All data were analyzed using SPSS medical statistical software (version 15.0). DFS was defined as the duration from the diagnosis of primary breast cancer to the date of LRR or DM or last follow-up; overall survival 1 (OS1) was defined as the period from the diagnosis of primary breast cancer to the date of patient death for any cause or last follow-up; overall survival 2 (OS2) was defined as the duration from the date of LRR or DM to the date of patient death for any cause or last follow-up. Both OS and DFS were analyzed using the Kaplan-Meier method. Comparisons of OS or DFS between groups were performed using log-rank test. A two-tailed *P* \< 0.05 was considered statistically significant. The Chi-squared test was performed to compare the distribution of patient characteristics between young and old patients. Multivariate analysis was done using Cox\'s proportional hazard regression model, and hazard ratios (HR) were presented with 95% confidential intervals (CI).
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